Barclays’s Coherus Oncology CHRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$330K Sell
195,473
-150,100
-43% -$267K ﹤0.01% 3424
2025
Q4
$491K Buy
345,573
+52,381
+18% +$76.3K ﹤0.01% 3857
2025
Q3
$481K Sell
293,192
-4,500
-2% -$5K ﹤0.01% 3838
2025
Q2
$218K Buy
297,692
+66,702
+29% +$57.6K ﹤0.01% 4219
2025
Q1
$186K Sell
230,990
-69,202
-23% -$79.6K ﹤0.01% 4082
2024
Q4
$414K Sell
300,192
-2,166,113
-88% -$2.43M ﹤0.01% 3943
2024
Q3
$2.56M Buy
2,466,305
+275,784
+13% +$378K ﹤0.01% 2646
2024
Q2
$3.79M Buy
2,190,521
+125,170
+6% +$252K ﹤0.01% 1706
2024
Q1
$4.94M Sell
2,065,351
-1,419,044
-41% -$3.49M ﹤0.01% 1865
2023
Q4
$11.6M Buy
3,484,395
+1,108,838
+47% +$2.97M ﹤0.01% 1406
2023
Q3
$8.88M Buy
2,375,557
+2,301,444
+3,105% +$10.6M 0.01% 1042
2023
Q2
$316K Sell
74,113
-114,403
-61% -$675K ﹤0.01% 3010
2023
Q1
$1.29M Sell
188,516
-110,490
-37% -$858K ﹤0.01% 2539
2022
Q4
$2.37M Buy
299,006
+94,202
+46% +$725K ﹤0.01% 2141
2022
Q3
$1.97M Buy
204,804
+162,448
+384% +$1.64M ﹤0.01% 1762
2022
Q2
$308K Sell
42,356
-12,104
-22% -$105K ﹤0.01% 3178
2022
Q1
$705K Sell
54,460
-42,230
-44% -$537K ﹤0.01% 2657
2021
Q4
$1.54M Sell
96,690
-35,533
-27% -$621K ﹤0.01% 2537
2021
Q3
$2.13M Buy
132,223
+24,757
+23% +$363K ﹤0.01% 2301
2021
Q2
$1.49M Sell
107,466
-41,118
-28% -$582K ﹤0.01% 2395
2021
Q1
$2.17M Sell
148,584
-494,432
-77% -$8.39M ﹤0.01% 2204
2020
Q4
$11.2M Buy
643,016
+301,709
+88% +$5.37M 0.01% 1120
2020
Q3
$6.26M Buy
341,307
+56,394
+20% +$1.05M ﹤0.01% 1270
2020
Q2
$5.09M Sell
284,913
-124,055
-30% -$2.1M ﹤0.01% 1372
2020
Q1
$6.63M Buy
408,968
+333,856
+444% +$6.17M 0.01% 1257
2019
Q4
$1.35M Sell
75,112
-12,108
-14% -$223K ﹤0.01% 3395
2019
Q3
$1.77M Buy
87,220
+47,315
+119% +$945K ﹤0.01% 3018
2019
Q2
$882K Buy
39,905
+19,622
+97% +$341K ﹤0.01% 3815
2019
Q1
$276K Buy
20,283
+17,687
+681% +$236K ﹤0.01% 4582
2018
Q4
$23K Sell
2,596
-76,975
-97% -$891K ﹤0.01% 5835
2018
Q3
$1.31M Buy
79,571
+56,954
+252% +$1.01M ﹤0.01% 3355
2018
Q2
$317K Buy
22,617
+12,245
+118% +$175K ﹤0.01% 4337
2018
Q1
$115K Buy
10,372
+2,793
+37% +$30.6K ﹤0.01% 5278
2017
Q4
$67K Sell
7,579
-1,060
-12% -$11.3K ﹤0.01% 5544
2017
Q3
$115K Sell
8,639
-13,008
-60% -$172K ﹤0.01% 4833
2017
Q2
$311K Buy
21,647
+3,136
+17% +$60.3K ﹤0.01% 3965
2017
Q1
$391K Buy
18,511
+16,302
+738% +$401K ﹤0.01% 3650
2016
Q4
$62K Sell
2,209
-2,594
-54% -$72.6K ﹤0.01% 5025
2016
Q3
$129K Buy
4,803
+4,186
+678% +$114K ﹤0.01% 4320
2016
Q2
$10K Buy
617
+342
+124% +$6.42K ﹤0.01% 5531
2016
Q1
$6K Sell
275
-443
-62% -$7.26K ﹤0.01% 5616
2015
Q4
$16K Buy
718
+595
+484% +$15.3K ﹤0.01% 5257
2015
Q3
$2K Sell
123
-329
-73% -$10K ﹤0.01% 6308
2015
Q2
$13K Buy
452
+244
+117% +$6.17K ﹤0.01% 5930
2015
Q1
$7K Sell
208
-180
-46% -$4.65K ﹤0.01% 6404
2014
Q4
$6K Buy
+388
New +$5.47K ﹤0.01% 6919

Other funds holding CHRS